Nov 27 (Reuters) - Colchicine, a commonly used anti-inflammatory drug, will be investigated as a possible treatment for COVID-19 in the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial, the ...

About The Study: In this randomized clinical trial, among adults with long COVID, colchicine did not improve functional capacity, respiratory function, or inflammatory markers. These findings ...

Depending on one’s perspective, the anti-inflammatory colchicine is either an unsung and underprescribed drug for patients with cardiovascular disease, or it’s an agent with limited clinical benefit ...

Scientists are uncovering a new possibility behind long COVID’s stubborn symptoms: hidden infections that awaken or emerge alongside SARS-CoV-2. Evidence is mounting that viruses like Epstein-Barr and ...